Hopp til innhold
NHI.no
Annonse

Seksuell dysfunksjon i overgangsalderen: Konklusjon

Innhold i artikkelen

Det finnes ingen ideell behandling av seksuell dysfunksjon i overgangsalderen. Selv om medikamenter er vist å ha noe effekt, så har de alle også bivirkninger. Det blir derfor ofte et vurderingsspørsmål som du bør drøfte med legen din, hvorvidt fordelene er så store at de overstiger ulempene med behandlingen.

Annonse

Vil du vite mer

Dette dokumentet er basert på det profesjonelle dokumentet Seksuell dysfunksjon i menopausen . Referanselisten for dette dokumentet vises nedenfor

  1. Gregersen N, Hilmand CB, Jensen PT, Giraldi AGE. Seksuel dysfunktion i menopausen. Ugeskr Læger 2006; 168: 559-63. PubMed
  2. Basson R, Berman J, Burnett A et al. Report of the international consensus development conference on female sexual dysfunction: definitions and classifications. J Urol 2000; 163: 888-93. PubMed
  3. Dennerstein L, Dudley E, Burger H. Are changes in sexual functioning during midlife due to aging or menopause? Fertil Steril 2001; 76: 456-60. PubMed
  4. Fugl-Meyer A, Fugl-Meyer KS. Sexual disabilities, problems and satisfaction in 18-74 year old swedes. Scand J Sexology 1999; 2: 79-106. PubMed
  5. Castelo-Branco C, Blumel JE, Araya H et al. Prevalence of sexual dysfunction in a cohort of middle-aged women: influences of menopause and hormone replacement therapy. J Obstet Gynaecol 2003; 23: 426-30. PubMed
  6. Köster A, Eplov LF, Garde K. Anticipations and experiences of menopause in a Danish female general population cohorte born in 1936. Arch Womens Ment Health 2002; 5: 9-13. PubMed
  7. Bachmann GA, Leiblum SR. The impact of hormones on menopausal sexuality: a literature review. Menopause 2004; 11: 120-30. PubMed
  8. Avis NE, Stellato R, Crawford S et al. Is there an association between menopause status and sexual functioning? Menopause 2000; 7: 297-309. PubMed
  9. Shufelt CL, Johnson BD, Berga SL, et al. Timing of hormone therapy, type of menopause, and coronary disease in women: data from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation. Menopause 2011; 18:943. PubMed
  10. Martin KA, Rosenson RS. Menopausal hormone therapy and cardiovascular risk. UpToDate, last updated Apr 18, 2019. UpToDate
  11. Bachmann G, Bancroft J, Braunstein G et al. Female androgen insufficiency: the Princeton consensus statement on definition, classification, and assessment. Fertil Steril 2002; 77: 660-5. PubMed
  12. Huang G, Basaria S, Travison TG, et al. Testosterone dose-response relationships in hysterectomized women with or without oophorectomy: effects on sexual function, body composition, muscle performance and physical function in a randomized trial. Menopause 2014; 21:612. PubMed
  13. Hays J, Ockene JK, Brunner RL, et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 2003; 348:1839. New England Journal of Medicine
  14. Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database of Systematic Reviews 2016, Issue 8. Art. No.: CD001500. Cochrane (DOI)
  15. Bachmann G, Bouchard C, Hoppe D, et al. Efficacy and safety of low-dose regimens of conjugated estrogens cream administered vaginally. Menopause 2009; 16: 719-27. PubMed
  16. Shifren JL, Davis SR. Androgens in postmenopausal women: a review. Menopause 2017; 24:970. PubMed
  17. Shifren JL, Braunstein GD, Simon JA et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 2000; 343: 682-8. New England Journal of Medicine
  18. Nijland EA, Weijmar Schultz WC, Nathorst-Boös J, et al. Tibolone and transdermal E2/NETA for the treatment of female sexual dysfunction in naturally menopausal women: results of a randomized active-controlled trial. J Sex Med 2008; 5:646. PubMed
  19. Dennerstein L, Lehert P. Modeling mid-aged women's sexual functioning: a prospective, population-based study. J Sex Marital Ther 2004; 30: 173-83. PubMed
Annonse
Annonse